Nanoscale HorizonsBioengineeringPeer-reviewed journal article
Enabling Organ- and Injury-Specific Nanocarrier Targeting via Surface-Functionalized PEG-b-PPS Micelles for Acute Kidney Injury
Boaz Bishop, Swagat H. Sharma, Ratnakar TiwariiD, Simseok A. YukiD, Sultan AlmunifiD, Susan E. QuagginiD, Evan Alexander ScottiD, Pinelopi P. KapitsinouiD
Abstract
While nanomedicine holds great promise for kidney disease, targeted delivery remains a major challenge. Most nanocarriers rely on passive accumulation or epithelial-specific ligands, limiting their utility in complex, inflamed renal environments. In acute kidney injury (AKI), inflammation and vascular dysfunction play central roles, yet targeting strategies beyond the tubule remain underexplored. Here, dual-ligand micelles are developed to enhance nanocarrier localization to the inflamed kidney by simultaneously engaging both organ- and injury-specific cues. Poly(ethylene glycol)-block-poly(propylene sulfide) (PEG-b-PPS) micelles were engineered to display two peptide ligands: CLPVASC, which preferentially distributes to the kidney, and CYNTTTHRC, which binds selectively to inflamed endothelium. These targeting motifs were incorporated via lipid-anchored peptide amphiphiles, enabling modular surface functionalization without disrupting micelle morphology, size, or charge. In vitro, dual-targeted micelles demonstrated enhanced uptake by human endothelial cells exposed to hypoxia-reoxygenation. In vivo, following unilateral renal ischemia-reperfusion injury (IRI) in mice, targeted micelles achieved selective accumulation in the injured kidney, outperforming both non-targeted controls and contralateral kidneys. Off-target distribution to liver, lung, and spleen was markedly reduced, confirming the spatial precision of the dual-ligand approach. This strategy offers a scalable, modular, and biologically informed platform for precision delivery in AKI and related inflammatory conditions.
- organism: mouse
- organism: human
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 2
- FWCI
- 0.42
- Field percentile
- 50th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oral Delivery of Kidney Targeting Nanotherapeutics for Polycystic Kidney Disease
Y. Huang, J. Wang, … E. J. Chung·bioRxiv·Oct 18, 2022
- Glomerulus-Targeted Nanotherapy via Collagen IV-α3 Binding Enhances Renal Immunoregulation in Lupus Nephritis
Lei Wang, Eleni Markoutsa, … Ruisheng Liu·Clinical SciencePeer-reviewed·Aug 5, 2026
- Avidity-controlled biotherapeutic delivery systems for the treatment of ischemia-reperfusion acute kidney injury
Arielle M. D’Elia, Kenneth M. Kim, … Christopher B. Rodell·bioRxiv·Oct 2, 2026
- Edaravone-Loaded Mesoscale Nanoparticles Treat Cisplatin-Induced Acute Kidney Injury
R. M. Williams, J. Shah, … D. A. Heller·bioRxiv·Jan 24, 2020
- Employing the intravesical delivery route to target on the kidney
Xinge Wang, Haiping Hu, … Xiao Z. Shen·American Journal of Physiology-Renal PhysiologyPeer-reviewed·Jan 17, 2026
- Targeting Protease-activated Receptor 4 (PAR4) Protects Against Acute Kidney Injury (AKI) in Ischemia Reperfusion Injury
Emma M. Webb, Shirong Cao, … Heidi E. Hamm·bioRxiv·Mar 30, 2026